Institutional Ownership
Crescent Biopharma Inc.
CUSIP G2545C104COMCBIOQ1 2026
13D / 13G Filings
9
Schedule 13D/13G on record
Beneficial Filers
8
Distinct reporting persons
Largest Stake
20.0%
Max % of class reported
Institutional Holders
57
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
9 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 9.5% | 2.67M | SEC |
| 2 | Feb 17, 2026 | Vestal Point Capital, LP | 13G | 5.4% | 1.50M | SEC |
| 3 | Feb 5, 2026 | Fmr LLC | 13G/A | 15.0% | 4.13M | SEC |
| 4 | Dec 11, 2025 | Forgrowth III Pa B.V. | 13G | 6.1% | 1.68M | SEC |
| 5 | Dec 8, 2025 | Fairmount Funds Management LLC | 13D/A | 18.5% | — | SEC |
| 6 | Oct 9, 2025 | Tang Capital Management, LLC | 13G | 5.0% | 700.0K | SEC |
| 7 | Aug 14, 2025 | Logos Global Management LP | 13G/A | 4.1% | — | SEC |
| 8 | Aug 14, 2025 | Biotechnology Value Fund L P | 13G/A | 10.0% | 1.39M | SEC |
| 9 | Jun 23, 2025 | Fairmount Funds Management LLC | 13D | 20.0% | — | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Fmr LLC | 4.13M | $75.93M |
| 2 | Bvf Inc/Il | 2.75M | $50.49M |
| 3 | Fairmount Funds Management LLC | 2.75M | $50.48M |
| 4 | Venrock Adviser, LLC | 2.13M | $39.19M |
| 5 | Fcpm III Services B.V. | 1.68M | $30.82M |
| 6 | Balyasny Asset Management L.P. | 1.51M | $27.74M |
| 7 | Vestal Point Capital, LP | 1.50M | $27.55M |
| 8 | Opaleye Management Inc. | 1.31M | $24.11M |
| 9 | Tang Capital Management LLC | 1.16M | $21.31M |
| 10 | Logos Global Management LP | 482.5K | $8.86M |